patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1 value | histology stringclasses 3 values | stage_at_diagnosis stringclasses 3 values | driver_mutation stringclasses 7 values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2 values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6 values | overall_survival_months float64 4 83 | censored bool 2 classes | msi_status stringclasses 2 values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1 value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_673904 | REC_0000401 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 15.5 | 75 | male | 2 | 20 | 5 | 4 | sotorasib 960 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:56.931411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_283785 | REC_0000402 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 16.8 | 74 | female | 2 | 10 | 6.3 | 5 | sotorasib 960 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:56.931642+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702797 | REC_0000403 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 12.2 | 69 | male | 1 | 19 | 7 | 2 | alectinib 600 mg BID | 24.6 | true | MSS | 2026-03-15T05:35:56.931880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745897 | REC_0000404 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 10 | 72 | female | 1 | 24 | 5.5 | 1 | entrectinib 600 mg daily | 15 | true | MSI-H | 2026-03-15T05:35:56.932344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183033 | REC_0000405 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 9.7 | 63 | male | 0 | 19 | 7.3 | 1 | entrectinib 600 mg daily | 12 | false | MSS | 2026-03-15T05:35:56.932653+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556631 | REC_0000406 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.9 | 57 | female | 1 | 56 | 5.2 | 8 | carboplatin + paclitaxel + pembrolizumab | 7.6 | false | MSS | 2026-03-15T05:35:56.932896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_524206 | REC_0000407 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 12.3 | 80 | male | 3 | 11 | 3.7 | 2 | osimertinib 80 mg daily | 36.1 | false | MSS | 2026-03-15T05:35:56.933152+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_901879 | REC_0000408 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 17.5 | 65 | male | 1 | 10 | 7.2 | 8 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:56.933390+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442097 | REC_0000409 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 9.1 | 72 | female | 2 | 26 | 4.8 | 3 | alectinib 600 mg BID | 8.4 | false | MSS | 2026-03-15T05:35:56.933628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_754257 | REC_0000410 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 18.1 | 73 | female | 2 | 1 | 8.3 | 2 | sotorasib 960 mg daily | 15.9 | true | MSS | 2026-03-15T05:35:56.933890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535758 | REC_0000411 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 10.2 | 71 | female | 1 | 12 | 4.5 | 5 | entrectinib 600 mg daily | 5.2 | true | MSS | 2026-03-15T05:35:56.934151+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_568645 | REC_0000412 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 12.2 | 59 | male | 1 | 25 | 5 | 6 | alectinib 600 mg BID | 11.3 | false | MSI-H | 2026-03-15T05:35:56.934417+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227165 | REC_0000413 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 11.3 | 68 | female | 0 | 14 | 5.3 | 7 | entrectinib 600 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:56.934674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847002 | REC_0000414 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 16 | 3.7 | 61 | male | 0 | 30 | 2.9 | 0 | pembrolizumab 200 mg q3w | 18.7 | true | MSS | 2026-03-15T05:35:56.934979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448190 | REC_0000415 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.4 | 67 | female | 1 | 32 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 4.1 | true | MSS | 2026-03-15T05:35:56.935318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275189 | REC_0000416 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 23 | 8.5 | 71 | female | 1 | 38 | 4.2 | 2 | pembrolizumab 200 mg q3w | 12.7 | false | MSS | 2026-03-15T05:35:56.935562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_523972 | REC_0000417 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 18 | 9.7 | 69 | female | 0 | 27 | 3.4 | 4 | pembrolizumab 200 mg q3w | 5.3 | false | MSS | 2026-03-15T05:35:56.935944+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573573 | REC_0000418 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 22 | 7.5 | 53 | male | 0 | 12 | 5 | 0 | alectinib 600 mg BID | 31.6 | true | MSS | 2026-03-15T05:35:56.936351+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439570 | REC_0000419 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 15.1 | 62 | female | 0 | 5 | 6.2 | 2 | sotorasib 960 mg daily | 15.1 | false | MSS | 2026-03-15T05:35:56.936631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_513734 | REC_0000420 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 11 | 71 | male | 1 | 11 | 6.9 | 2 | alectinib 600 mg BID | 11.6 | true | MSS | 2026-03-15T05:35:56.936885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888463 | REC_0000421 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 11.3 | 73 | female | 1 | 19 | 3.4 | 0 | sotorasib 960 mg daily | 22.8 | false | MSS | 2026-03-15T05:35:56.937126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824790 | REC_0000422 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7.4 | 56 | male | 0 | 12 | 5.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.2 | false | MSS | 2026-03-15T05:35:56.937361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105900 | REC_0000423 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 16 | 12.3 | 76 | female | 2 | 20 | 3.9 | 2 | entrectinib 600 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:56.937600+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987199 | REC_0000424 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 28 | 17.8 | 55 | female | 0 | 15 | 4.4 | 0 | sotorasib 960 mg daily | 11.6 | false | MSS | 2026-03-15T05:35:56.937840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902862 | REC_0000425 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13.6 | 52 | female | 0 | 21 | 5.9 | 6 | entrectinib 600 mg daily | 8 | false | MSS | 2026-03-15T05:35:56.938078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990588 | REC_0000426 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 17 | 5 | 71 | female | 1 | 25 | 6.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 19.5 | true | MSS | 2026-03-15T05:35:56.938306+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101865 | REC_0000427 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 13.3 | 80 | female | 2 | 19 | 6 | 2 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:35:56.938540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_540018 | REC_0000428 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 14.4 | 72 | male | 2 | 16 | 6.3 | 5 | osimertinib 80 mg daily | 12.8 | false | MSI-H | 2026-03-15T05:35:56.938787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832159 | REC_0000429 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 13.2 | 70 | male | 1 | 19 | 6.6 | 5 | sotorasib 960 mg daily | 8.7 | false | MSS | 2026-03-15T05:35:56.939041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_372184 | REC_0000430 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 15 | 72 | female | 2 | 8 | 5.1 | 1 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:35:56.939489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641910 | REC_0000431 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 15.7 | 60 | male | 1 | 8 | 4.6 | 5 | alectinib 600 mg BID | 4 | true | MSI-H | 2026-03-15T05:35:56.939828+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763467 | REC_0000432 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.4 | 71 | male | 1 | 73 | 7.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:35:56.940170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304265 | REC_0000433 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 7.1 | 70 | female | 2 | 21 | 5.5 | 2 | pembrolizumab 200 mg q3w | 26.6 | false | MSS | 2026-03-15T05:35:56.940415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937400 | REC_0000434 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.7 | 62 | male | 1 | 20 | 6 | 5 | sotorasib 960 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:35:56.940692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234133 | REC_0000435 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5 | 51 | male | 0 | 47 | 4.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 16.7 | false | MSS | 2026-03-15T05:35:56.940977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691408 | REC_0000436 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 4.2 | 62 | male | 0 | 56 | 5.5 | 6 | pembrolizumab 200 mg q3w | 6.8 | false | MSS | 2026-03-15T05:35:56.941233+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_234359 | REC_0000437 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.6 | 61 | female | 1 | 10 | 7.1 | 4 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:56.941486+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630322 | REC_0000438 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 2.1 | 75 | female | 2 | 46 | 4.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:56.941716+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543574 | REC_0000439 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 29 | 5.1 | 71 | female | 2 | 24 | 5.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 43.1 | true | MSS | 2026-03-15T05:35:56.941949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_193090 | REC_0000440 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 10.3 | 77 | female | 1 | 15 | 5.3 | 5 | sotorasib 960 mg daily | 13.9 | false | MSI-H | 2026-03-15T05:35:56.942199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113253 | REC_0000441 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 15 | 14.1 | 54 | female | 0 | 4 | 5.5 | 4 | pembrolizumab 200 mg q3w | 12.1 | false | MSS | 2026-03-15T05:35:56.942443+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704826 | REC_0000442 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 13.4 | 72 | female | 2 | 15 | 4.1 | 1 | pembrolizumab 200 mg q3w | 10.8 | true | MSS | 2026-03-15T05:35:56.942683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241491 | REC_0000443 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 10 | 63 | female | 1 | 20 | 5.8 | 8 | pembrolizumab 200 mg q3w | 11.4 | false | MSI-H | 2026-03-15T05:35:56.943021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_981126 | REC_0000444 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 11.2 | 68 | female | 1 | 18 | 5.7 | 4 | sotorasib 960 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:56.943258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963033 | REC_0000445 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 5 | 56 | female | 1 | 48 | 5.8 | 7 | pembrolizumab 200 mg q3w | 16.1 | false | MSS | 2026-03-15T05:35:56.943493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246538 | REC_0000446 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 21 | 8.8 | 56 | female | 1 | 87 | 2.5 | 2 | pembrolizumab 200 mg q3w | 22.4 | false | MSS | 2026-03-15T05:35:56.943727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271898 | REC_0000447 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 4.5 | 74 | female | 1 | 75 | 5.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:56.943961+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_947278 | REC_0000448 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 35 | 4.3 | 63 | male | 1 | 43 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.2 | true | MSS | 2026-03-15T05:35:56.944353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731658 | REC_0000449 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 5.4 | 57 | female | 0 | 19 | 3.9 | 1 | pembrolizumab 200 mg q3w | 19.8 | true | MSS | 2026-03-15T05:35:56.944645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319624 | REC_0000450 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 16.3 | 66 | female | 0 | 21 | 5.3 | 6 | osimertinib 80 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:56.944912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731594 | REC_0000451 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 9.8 | 60 | female | 1 | 18 | 5 | 1 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:56.945154+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_126363 | REC_0000452 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 8.6 | 56 | female | 0 | 49 | 3.9 | 8 | carboplatin + paclitaxel + pembrolizumab | 11.5 | false | MSS | 2026-03-15T05:35:56.945416+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132367 | REC_0000453 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 15 | 16.5 | 72 | female | 1 | 10 | 4.7 | 5 | osimertinib 80 mg daily | 22.5 | true | MSS | 2026-03-15T05:35:56.945652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_743409 | REC_0000454 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 13.4 | 48 | male | 0 | 16 | 4.2 | 6 | osimertinib 80 mg daily | 7.7 | false | MSI-H | 2026-03-15T05:35:56.945889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319366 | REC_0000455 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.3 | 48 | female | 0 | 15 | 6.2 | 2 | pembrolizumab 200 mg q3w | 38.6 | false | MSS | 2026-03-15T05:35:56.946126+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573596 | REC_0000456 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 24 | 7.7 | 67 | female | 0 | 13 | 5.8 | 7 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:35:56.946421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_456876 | REC_0000457 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 7.6 | 73 | female | 0 | 62 | 4.8 | 0 | carboplatin + paclitaxel + pembrolizumab | 58.9 | false | MSS | 2026-03-15T05:35:56.946655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_292645 | REC_0000458 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 7.4 | 62 | male | 0 | 9 | 3.7 | 2 | entrectinib 600 mg daily | 31.4 | false | MSS | 2026-03-15T05:35:56.946887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364867 | REC_0000459 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 28 | 4.6 | 64 | female | 1 | 8 | 5.5 | 1 | entrectinib 600 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:56.947122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_732204 | REC_0000460 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 8.9 | 62 | female | 0 | 24 | 5.5 | 2 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:56.947352+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756273 | REC_0000461 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.7 | 60 | male | 1 | 18 | 5.4 | 1 | sotorasib 960 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:56.947589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_641721 | REC_0000462 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 16 | 11.7 | 61 | male | 0 | 26 | 5 | 1 | alectinib 600 mg BID | 14.1 | true | MSS | 2026-03-15T05:35:56.947824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954237 | REC_0000463 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 10.9 | 71 | female | 1 | 17 | 4.3 | 1 | pembrolizumab 200 mg q3w | 15.2 | true | MSI-H | 2026-03-15T05:35:56.948055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127060 | REC_0000464 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.6 | 68 | male | 0 | 39 | 6.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.8 | false | MSS | 2026-03-15T05:35:56.948453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383683 | REC_0000465 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 12.7 | 73 | female | 2 | 4 | 5.7 | 7 | osimertinib 80 mg daily | 17.4 | false | MSI-H | 2026-03-15T05:35:56.948697+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_408673 | REC_0000466 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 9.3 | 54 | male | 0 | 22 | 2.9 | 3 | alectinib 600 mg BID | 13.7 | false | MSS | 2026-03-15T05:35:56.948962+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_305999 | REC_0000467 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.9 | 73 | female | 1 | 17 | 5.9 | 4 | entrectinib 600 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:56.949231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903561 | REC_0000468 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 13.1 | 62 | male | 1 | 19 | 7.1 | 5 | sotorasib 960 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:56.949475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723522 | REC_0000469 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 7.3 | 70 | female | 1 | 19 | 7.7 | 5 | osimertinib 80 mg daily | 15.8 | true | MSS | 2026-03-15T05:35:56.949796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991069 | REC_0000470 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.3 | 50 | male | 0 | 49 | 4.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:56.950049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844410 | REC_0000471 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 11.5 | 66 | male | 0 | 17 | 7 | 5 | osimertinib 80 mg daily | 15.4 | true | MSI-H | 2026-03-15T05:35:56.950292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_614127 | REC_0000472 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 13.3 | 74 | female | 3 | 19 | 5.3 | 6 | pembrolizumab 200 mg q3w | 12.5 | false | MSS | 2026-03-15T05:35:56.950536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713061 | REC_0000473 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 5.5 | 67 | male | 1 | 12 | 2 | 4 | entrectinib 600 mg daily | 6.4 | true | MSS | 2026-03-15T05:35:56.950779+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271333 | REC_0000474 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.9 | 61 | female | 1 | 12 | 7.7 | 2 | osimertinib 80 mg daily | 25.3 | false | MSS | 2026-03-15T05:35:56.951011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467011 | REC_0000475 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 6.7 | 67 | male | 1 | 36 | 4.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.5 | false | MSS | 2026-03-15T05:35:56.951245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252659 | REC_0000476 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 2.6 | 67 | female | 1 | 44 | 5.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.6 | true | MSS | 2026-03-15T05:35:56.951474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688304 | REC_0000477 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 18 | 9.4 | 71 | female | 3 | 22 | 5 | 0 | entrectinib 600 mg daily | 20 | false | MSS | 2026-03-15T05:35:56.951712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_167780 | REC_0000478 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 17.7 | 58 | female | 1 | 10 | 4.2 | 7 | sotorasib 960 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:56.951954+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893992 | REC_0000479 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 29 | 6.8 | 84 | female | 1 | 14 | 2.8 | 6 | pembrolizumab 200 mg q3w | 15 | false | MSS | 2026-03-15T05:35:56.952235+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812791 | REC_0000480 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 14.4 | 54 | male | 0 | 21 | 5.6 | 1 | entrectinib 600 mg daily | 23 | false | MSI-H | 2026-03-15T05:35:56.952481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_120884 | REC_0000481 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 20 | 6.3 | 60 | male | 1 | 18 | 6.3 | 0 | sotorasib 960 mg daily | 55.7 | true | MSS | 2026-03-15T05:35:56.952715+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909518 | REC_0000482 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 10.7 | 62 | female | 1 | 11 | 5.6 | 3 | entrectinib 600 mg daily | 10.2 | true | MSI-H | 2026-03-15T05:35:56.953033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746853 | REC_0000483 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 12.3 | 71 | female | 0 | 11 | 4.9 | 2 | sotorasib 960 mg daily | 26.3 | true | MSS | 2026-03-15T05:35:56.953274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661456 | REC_0000484 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 3.2 | 71 | male | 2 | 63 | 5 | 1 | carboplatin + paclitaxel + pembrolizumab | 11.4 | true | MSS | 2026-03-15T05:35:56.953511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291757 | REC_0000485 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 10.1 | 74 | female | 2 | 11 | 7.1 | 7 | alectinib 600 mg BID | 8.3 | true | MSS | 2026-03-15T05:35:56.953743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366661 | REC_0000486 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 13.3 | 79 | female | 0 | 6 | 6.9 | 9 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:35:56.953974+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386730 | REC_0000487 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 9.1 | 60 | male | 1 | 11 | 4.6 | 1 | osimertinib 80 mg daily | 13.7 | false | MSS | 2026-03-15T05:35:56.954209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_343640 | REC_0000488 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.1 | 60 | male | 1 | 10 | 5 | 3 | alectinib 600 mg BID | 10.1 | true | MSI-H | 2026-03-15T05:35:56.954444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_564873 | REC_0000489 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.1 | 63 | female | 0 | 15 | 5 | 6 | alectinib 600 mg BID | 4.3 | true | MSS | 2026-03-15T05:35:56.954685+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773571 | REC_0000490 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 26 | 15.4 | 83 | female | 1 | 12 | 5.5 | 0 | sotorasib 960 mg daily | 30.6 | false | MSS | 2026-03-15T05:35:56.954922+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_835579 | REC_0000491 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 6.5 | 53 | female | 0 | 16 | 6.2 | 6 | pembrolizumab 200 mg q3w | 14.6 | false | MSS | 2026-03-15T05:35:56.955162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487853 | REC_0000492 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 12.4 | 64 | female | 0 | 15 | 8.2 | 1 | entrectinib 600 mg daily | 17.4 | true | MSI-H | 2026-03-15T05:35:56.955418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904363 | REC_0000493 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 13.3 | 71 | male | 2 | 13 | 7.2 | 2 | entrectinib 600 mg daily | 17 | true | MSI-H | 2026-03-15T05:35:56.955682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760013 | REC_0000494 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.8 | 69 | male | 0 | 13 | 6.1 | 5 | alectinib 600 mg BID | 7.1 | false | MSI-H | 2026-03-15T05:35:56.955930+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_258985 | REC_0000495 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 8.1 | 60 | female | 0 | 10 | 5.1 | 2 | alectinib 600 mg BID | 21.7 | true | MSS | 2026-03-15T05:35:56.956379+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476043 | REC_0000496 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 15.9 | 73 | female | 1 | 20 | 4.8 | 1 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:56.956631+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_974995 | REC_0000497 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 17 | 12.4 | 70 | female | 1 | 9 | 6.9 | 1 | entrectinib 600 mg daily | 16.7 | false | MSI-H | 2026-03-15T05:35:56.956867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296052 | REC_0000498 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 11.9 | 73 | female | 2 | 16 | 4.8 | 5 | pembrolizumab 200 mg q3w | 13.9 | false | MSS | 2026-03-15T05:35:56.957100+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109344 | REC_0000499 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 9.6 | 90 | female | 2 | 14 | 6.2 | 1 | osimertinib 80 mg daily | 24.6 | true | MSS | 2026-03-15T05:35:56.957327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900671 | REC_0000500 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 4.9 | 69 | female | 0 | 25 | 5.6 | 1 | osimertinib 80 mg daily | 8 | true | MSS | 2026-03-15T05:35:56.957556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.